What Are Wall Street Analysts' Target Price for Abbott Stock?

With a market cap of $190.2 billion, Abbott Laboratories (ABT) is a global healthcare company that develops, manufactures, and sells a wide range of products across pharmaceuticals, diagnostics, nutrition, and medical devices. It provides innovative healthcare solutions including generic medicines, diagnostic systems, nutritional products, cardiovascular devices, and diabetes care technologies worldwide.

Shares of the Abbott Park, Illinois-based company have underperformed the broader market over the past 52 weeks. ABT stock has decreased 12.5% over this time frame, while the broader S&P 500 Index ($SPX) has gained 12.2%. Moreover, the stock has declined 11.8% on a YTD basis, compared to SPX's 10.3% rise.

Looking closer, shares of the medical device maker have also lagged behind the State Street Health Care Select Sector SPDR ETF's (XLV) 28.9% return over the past 52 weeks.

Abbott shares fell 1.9% on Oct. 21 after the company cut its 2026 sales-growth forecast to about 6% from 6.5% - 7.5%, raising concerns about its underlying business momentum and 2027 growth trajectory. Medical-device revenue missed expectations, mainly due to weaker-than-expected heart-device sales, while the nutrition business faced ongoing pressure from the loss of a major U.S. government supply contract, higher manufacturing costs, weaker demand and costly litigation involving its infant formula products. Although Q3 2026 adjusted EPS of $1.42 matched estimates and revenue of $13.01 billion slightly exceeded the consensus, the planned 2027 spin-off of the nutrition division did not offset concerns over the reduced growth outlook.

For the fiscal year ending in December 2026, analysts expect Abbott’s adjusted EPS to grow 7.2% year-over-year to $5.52. The company's earnings surprise history is mixed. It topped or met the consensus estimates in three of the last four quarters while missing on another occasion.

Among the 29 analysts covering the stock, the consensus rating is a “Strong Buy.” That’s based on 21 “Strong Buy” ratings, two “Moderate Buys,” and six “Holds.” 

This configuration is more bullish than three months ago, with 19 analysts suggesting a "Strong Buy."  

On Nov. 9, BofA analyst Travis Steed raised Abbott’s price target to $125 and maintained a "Buy" rating.

The mean price target of $118.42 represents a premium of 7.2% to ABT's current levels. The Street-high price target of $130, implying a potential upside of 17.6% from the current price levels.

On the date of publication, Sohini Mondal did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.